Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
Last trade$0.6317
Day change-$0.0483 (-7.10%)
Day range$0.635 – $0.722
Volume143,317
Market cap$26M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$25.71M
Price / earnings
—
Price / book
0.28×
Price / sales
3.63×
EV / sales
-1.47×
EV / EBITDA
0.11×
Profitability
Earnings per share
-$2.49
Return on assets
-59.85%
Return on equity
-101.08%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.43×
Quick ratio
3.43×
Cash ratio
1.12×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$83.53M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MGX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$2.18M
-$257K
$1.25M
$3.91M
$8.66M
$8.51M
$4.13M
$9.61M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$2.18M
-$257K
$1.25M
$3.91M
$8.66M
$8.51M
$4.13M
$9.61M
Selling, general and administrative
$6.88M
$6M
$6.54M
$6.78M
$6.22M
$6.99M
$6.81M
$7.07M
Research and development
$17.53M
$22.51M
$19.3M
$21.5M
$25.28M
$22.51M
$25.14M
$23.16M
Total operating expenses
$24.41M
$28.52M
$25.84M
$28.28M
$31.5M
$29.5M
$31.95M
$30.24M
Operating income
-$22.23M
-$28.77M
-$24.59M
-$24.37M
-$22.84M
-$20.99M
-$27.82M
-$20.62M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$21.13M
-$27.48M
-$23.05M
-$22.49M
-$20.63M
-$19.86M
-$24.94M
-$24.61M
Income taxes
$0
$0
$10K
$34K
-$234K
$44K
$98K
-$1.21M
Net income
-$21.13M
-$27.48M
-$23.06M
-$22.53M
-$20.39M
-$19.91M
-$25.04M
-$23.4M
Net income attributable to common shareholders
-$21.13M
-$27.48M
-$23.06M
-$22.53M
-$20.39M
-$19.91M
-$25.04M
-$23.4M
EBITDA
-$20.97M
-$27.51M
-$23.31M
-$23.07M
-$21.52M
-$19.65M
-$26.46M
-$19.16M
Basic earnings per share
-$0.56
-$0.73
-$0.61
-$0.60
-$0.55
-$0.54
-$0.68
-$0.62
Diluted earnings per share
-$0.56
-$0.73
-$0.61
-$0.60
-$0.55
-$0.54
-$0.68
-$0.62
Recent news
Company coverage with links to the original publishers.
Metagenomi Therapeutics announced that CEO Jian Irish will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026. The company remains on track to submit an IND application in Q4 2026 for MGX-001, its lead hemophilia A treatment program utilizing proprietary CRISPR gene-editing technology.
Over 50 pharmaceutical companies are advancing 55+ pipeline hemophilia drugs across various clinical development stages. Key players including Novo Nordisk, Roche, Regeneron, and others are developing innovative therapies with mechanisms like FVIII mimetics, gene therapies, and factor replacement treatments. Recent developments include Novo Nordisk's FDA submission for denecimig and Metagenomi's progress toward clinical trials for gene-editing therapy MGX-001.
Metagenomi Therapeutics announced a publication in Nature Structural & Molecular Biology highlighting MG119-28, a compact CRISPR nuclease demonstrating superior editing efficiency compared to previous compact nucleases. The nuclease showed 64% knockdown of target protein in mice via single AAV injection, supporting the company's path toward clinically relevant genome editing systems deliverable via AAV for non-hepatic indications including neuromuscular diseases.
Metagenomi presented data at the ASGCT Annual Meeting 2025, showcasing advancements in its gene editing technologies, including compact nucleases for extrahepatic gene editing and CAST for site-specific integration of large therapeutic genes.
Metagenomi, a precision genetic medicines company, announced upcoming scientific presentations and provided updates on its gene editing technology and pipeline. The company highlighted positive results from a nonhuman primate study for its hemophilia A treatment and advancements in its CRISPR-associated transposase (CAST) systems.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.